Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Iovance Biotherapeutics (IOVA) over the last 15 years, with Dec 2024 value amounting to $304.8 million.

  • Iovance Biotherapeutics' Shares Outstanding (Weighted Average) rose 19.22% to $361.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $361.9 million, marking a year-over-year increase of 19.22%. This contributed to the annual value of $304.8 million for FY2024, which is 19.09% up from last year.
  • According to the latest figures from FY2024, Iovance Biotherapeutics' Shares Outstanding (Weighted Average) is $304.8 million, which was up 19.09% from $255.9 million recorded in FY2023.
  • Iovance Biotherapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $304.8 million for FY2024, and its period low was $146.7 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $255.9 million (2023), whereas its average is $239.5 million.
  • Data for Iovance Biotherapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 62.14% (in 2023) over the last 5 years.
  • Over the past 5 years, Iovance Biotherapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $146.7 million in 2020, then climbed by 6.96% to $156.9 million in 2021, then grew by 0.60% to $157.8 million in 2022, then spiked by 62.14% to $255.9 million in 2023, then rose by 19.09% to $304.8 million in 2024.